Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of Ethane-1-Hydroxyl-1, 1-Diphosphonate (EHDP) on experimental and clinical heterotopic ossification was studied. Demineralized cortical bone matrix was implanted in the abdominal wall of three groups of adult male rats. Two groups received injections amounting to 5 and 20 mg/kg/day of EHDP, respectively, and a control group received placebo. The lower dose of EHDP had no effect on bone formation, whereas the higher dose resulted in a marked reduction in ash content and 45Ca uptake in the implants. Inhibitory effects on heterotopic bone and serum alkaline phosphatase activity were observed when treating with high doses (50 mg/kg/day) a paraplegic patient following resection of para-articular ossifications around the hips. The effect of EHDP on bone formation is interpreted as reflecting a dose-dependent interference with the deposition of hydroxyapatite crystals in the bone matrix.
 ...
PMID:High doses of the diphosphonate EHDP for the prevention of heterotopic ossification. An experimental and clinical study. 310 23

Ethane-I-hydroxy-I,I-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated patients with these clinical manifestations.
 ...
PMID:Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. 641 43

Heterotopic ossification (HO) following neurological injury is defined as soft tissue bone formation which is most often seen after spinal cord or head injury and reported to occur after numerous other neurological insults. It can result in ankylosis of associated joints restricting patient mobility. Lesions present with signs of local inflammation. Evidence of ossification is noted on Technetium 99 bone scan and then on X-ray. Serum alkaline phosphatase may be elevated. Although it resembles the histopathology of myositis ossificans traumatica, its pathogenesis remains unclear. Current research favors exercise of joints to attenuate loss in range of motion. Ethane-1-hydroxy-1, 1-diphosphonic acid, a diphosphonate analogue of pyrophosphate, is the only medical treatment specifically indicated in heterotopic ossification. It has not been as effective as first hoped. Nonsteroidal anti-inflammatory drugs, warfarin, and X-radiation therapy hold promise as treatments. Surgical excision to remove ankylosing ectopic bone has been plagued by reoccurrence. Studies to better elucidate the etiology of HO, accelerate diagnosis of the condition, and accurately determine its risk of reoccurrence are needed. Further controlled studies of the various treatments are also warranted.
...
PMID:Neurogenic heterotopic ossification. 2452 72